Are Monoamine Oxidase Inhibitors (MAOIs) safe as Pro Re Nata (PRN) medications for anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MAOIs Are Not Appropriate for PRN Use in Anxiety

MAOIs should never be used as PRN (as-needed) medications for anxiety. These medications require continuous daily dosing to achieve therapeutic effect and carry significant safety risks that make intermittent use both ineffective and dangerous.

Why MAOIs Cannot Be Used PRN

Pharmacological Requirements

  • MAOIs require 2-4 weeks of continuous daily dosing to achieve therapeutic effect for anxiety disorders, making them fundamentally incompatible with PRN use 1, 2.
  • The mechanism of action involves irreversible enzyme inhibition that takes weeks to produce clinical benefit and requires steady-state levels 3.
  • Treatment with MAOIs "often has to be long-term," and discontinuation can lead to withdrawal symptoms and loss of efficacy 4, 1.

Critical Safety Concerns

  • Dietary restrictions must be maintained continuously while on MAOIs, not just when taking individual doses 5.
  • Patients must avoid tyramine-rich foods (aged cheeses, pickled herring, beer, wine, liver, dry sausage) at all times during MAOI therapy to prevent hypertensive crisis 5.
  • The risk of hypertensive crisis persists for at least 14 days after discontinuing an MAOI due to the time required for enzyme regeneration 4, 5.

Dangerous Drug Interactions

  • MAOIs are absolutely contraindicated with numerous medications commonly used for acute symptoms 4, 6, 5:

    • All SSRIs and SNRIs (risk of serotonin syndrome)
    • Sympathomimetic decongestants like pseudoephedrine and phenylephrine (risk of hypertensive crisis)
    • Dextromethorphan in cough medications
    • Meperidine and certain other opioids
    • Stimulants of any kind
  • Required washout periods make intermittent use impossible: 2 weeks after stopping MAOIs before starting other medications, and 5 weeks after fluoxetine before starting MAOIs 4, 6, 5.

Appropriate PRN Options for Anxiety

First-Line PRN Medications

  • Benzodiazepines (lorazepam, clonazepam) are the preferred PRN agents for acute anxiety, as they work through GABA mechanisms with rapid onset and no serotonergic effects 7.
  • These medications are effective for both acute and chronic anxiety symptoms when used appropriately 7.

When MAOIs Are Appropriate (But Not PRN)

  • MAOIs are effective for continuous daily treatment of specific anxiety disorders, particularly agoraphobia, panic disorder, and mixed anxiety-depressive states 8, 1, 2.
  • Phenelzine has been shown effective for social phobias and agoraphobia when used as scheduled daily medication 9, 10.
  • Current guidelines recommend MAOIs as third- to fifth-line treatments for anxiety disorders due to safety concerns, reserved for treatment-resistant cases 8, 3.

Critical Clinical Pitfalls

  • Never prescribe MAOIs without comprehensive patient education about dietary restrictions, drug interactions, and the need for continuous use 4.
  • Patients must be warned to avoid all over-the-counter cold/allergy medications containing sympathomimetics and to inform all healthcare providers about MAOI use before receiving any new medications 4, 5.
  • Failure to maintain adequate washout periods when switching between MAOIs and other antidepressants is the most common cause of preventable serotonin syndrome 4, 6.

References

Research

Monoamine oxidase inhibitors in anxiety disorders.

Journal of psychiatric research, 1988

Research

[Indications for therapy using MAO inhibitors].

Psychiatrische Praxis, 1989

Guideline

Monoamine Oxidase Inhibitors (MAOIs) in the Treatment of Depression and Anxiety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Antidepressant Combinations with MAOIs: Safety Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Medication Options for Anxiety and Depression in Patients with History of Serotonin Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Use of MAOI antidepressants.

American family physician, 1978

Research

Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.

Journal of neural transmission. Supplementum, 1989

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.